Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups

Blood Cancer J. 2016 Jan 22;6(1):e389. doi: 10.1038/bcj.2015.115.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibody-Dependent Cell Cytotoxicity
  • B-Lymphocytes / immunology*
  • B-Lymphocytes / metabolism*
  • B-Lymphocytes / pathology
  • Female
  • Humans
  • Interleukin-10 / metabolism*
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukemia, Lymphocytic, Chronic, B-Cell / etiology*
  • Leukemia, Lymphocytic, Chronic, B-Cell / metabolism*
  • Male
  • Polymorphism, Genetic*
  • Receptors, IgG / genetics*
  • Rituximab / administration & dosage
  • Rituximab / therapeutic use*
  • Treatment Outcome

Substances

  • FCGR3A protein, human
  • Receptors, IgG
  • Interleukin-10
  • Rituximab